Market Tracker

02/23 5:16pm ET

Clovis Oncology Inc (NASDAQ:CLVS)

57.71
Delayed Data
As of Feb 23
 -3.48 / -5.69%
Today’s Change
11.57
Today|||52-Week Range
67.16
+29.92%
Year-to-Date
Clovis (CLVS) Q4 Loss Wider than Expected; Focus on Rubraca
Feb 23 / Zacks.com - Paid Partner Content
Here's Why M&A Has Tesaro's Stock Soaring 40% In 2017
Feb 10 / MotleyFool.com - Paid Partner Content
Clovis, Tesaro Soar on Astrazeneca Phase Three News
Feb 17 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close61.19
Today’s open62.41
Day’s range56.81 - 63.83
Volume3,280,618
Average volume (3 months)2,158,777
Market cap$2.7B
Dividend yield--
Data as of 4:00pm ET, 02/23/2017

Growth & Valuation

Earnings growth (last year)-107.42%
Earnings growth (this year)+8.52%
Earnings growth (next 5 years)+29.42%
Revenue growth (last year)-100.00%
P/E ratioNM
Price/Sales--
Price/Book7.81

Competitors

 Today’s
change
Today’s
% change
AKRXAkorn Inc+0.01+0.05%
HZNPHorizon Pharma PLC+0.11+0.65%
ENDPEndo International P...+0.50+3.88%
CBPOChina Biologic Produ...+2.97+2.77%
Data as of 4:00pm ET, 02/23/2017

Financials

Next reporting dateMay 9, 2017
EPS forecast (this quarter)-$1.46
Annual revenue (last year)$0.00
Annual profit (last year)-$352.9M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Patrick J. Mahaffy
SVP-Finance, Chief Financial &
Accounting Officer
Daniel W. Muehl
Corporate headquarters
Boulder, Colorado

Forecasts